Get the Stockscreener App
9.60
0.00%
0.00
After Hours:
9.67
0.07
+0.73%
Organon Co stock is traded at $9.60, with a volume of 3.15M.
It is up +0.00% in the last 24 hours and down -9.86% over the past month.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
See More
Previous Close:
$9.60
Open:
$9.66
24h Volume:
3.15M
Relative Volume:
0.80
Market Cap:
$2.50B
Revenue:
$6.29B
Net Income/Loss:
$750.00M
P/E Ratio:
3.3333
EPS:
2.88
Net Cash Flow:
$586.00M
1W Performance:
-11.44%
1M Performance:
-9.86%
6M Performance:
-14.13%
1Y Performance:
-46.67%
1-Day Range:
$9.58
$9.79
1-Week Range:
$9.56
$10.88
52-Week Range:
$8.01
$19.05
Organon Co Stock (OGN) Company Profile
Name
Organon Co
Sector
Industry
Phone
551-430-6000
Address
30 HUDSON STREET, JERSEY CITY
Compare OGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
9.60 | 2.50B | 6.29B | 750.00M | 586.00M | 2.88 |
|
LLY
Lilly Eli Co
|
819.40 | 747.19B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
190.90 | 459.32B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
230.30 | 407.19B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
NVS
Novartis Ag Adr
|
129.12 | 251.72B | 53.40B | 13.68B | 16.89B | 6.8864 |
|
MRK
Merck Co Inc
|
85.70 | 214.78B | 63.43B | 16.42B | 14.72B | 6.4861 |
Organon Co Stock (OGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-02-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-06-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-03-23 | Downgrade | Goldman | Buy → Neutral |
| Sep-21-23 | Initiated | Barclays | Overweight |
| Mar-16-23 | Initiated | Raymond James | Outperform |
| Oct-14-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-06-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-07-21 | Initiated | Piper Sandler | Neutral |
| Sep-01-21 | Initiated | BofA Securities | Buy |
| Jul-22-21 | Initiated | Citigroup | Buy |
| Jun-15-21 | Initiated | JP Morgan | Neutral |
| Jun-11-21 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-10-21 | Initiated | Evercore ISI | Outperform |
View All
Organon Co Stock (OGN) Latest News
What analysts say about Organon Co stockVolume Profile Analysis & Next-Level Stock Intelligence, Now Free - earlytimes.in
Are OGN’s Debt Reduction Efforts Enough to Shift Market Perception on Long-Term Growth? - simplywall.st
DexCom, Masimo, Integer Holdings, The Pennant Group, and Organon Stocks Trade Down, What You Need To Know - FinancialContent
Organon & Co.'s (OGN) "Sell (D+)" Rating Reiterated at Weiss Ratings - MarketBeat
Organon jumps despite Q2 revenue dip as revised outlook exceeds consensus - MSN
Q2 Earnings Highs And Lows: Organon (NYSE:OGN) Vs The Rest Of The Branded Pharmaceuticals Stocks - The Globe and Mail
Is There Now Opportunity in Organon Stock After Recent Double Digit Drop in 2025? - Yahoo
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know - Yahoo Finance
Is Organon a Hidden Bargain After Shares Drop Nearly 40% in 2024? - simplywall.st
Organon (OGN) Stock Slides as Market Rises: Facts to Know Before You Trade - sharewise.com
Will Organon (OGN) Beat Estimates Again in Its Next Earnings Report? - sharewise.com
Is Organon (NYSE:OGN) A Risky Investment? - 富途牛牛
Is Organon Co a good long term investmentInterest Rate Changes & Advanced Stock Screening Tools - earlytimes.in
Public Employees Retirement System of Ohio Sells 23,948 Shares of Organon & Co. $OGN - MarketBeat
3 Reasons To Avoid OGN And 1 Stock To Buy Instead - Barchart.com
3 Reasons to Avoid OGN and 1 Stock to Buy Instead - The Globe and Mail
Organon (NYSE:OGN) Has No Shortage Of Debt - 富途牛牛
Organon & Co trades in the red for seven straight sessions - MSN
Organon & Co. (NYSE:OGN) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Co. (7XP) stock good for long term investingJuly 2025 Big Picture & High Accuracy Trade Signal Alerts - newser.com
Organon & Co. $OGN Shares Acquired by Cantor Fitzgerald Investment Advisors L.P. - MarketBeat
Organon & Co. $OGN Shares Purchased by State of Alaska Department of Revenue - MarketBeat
AbbVie, AMN Healthcare Services, LeMaitre, Waters Corporation, and Organon Shares Skyrocket, What You Need To Know - Yahoo
Organon (OGN) Shares Skyrocket, What You Need To Know - MSN
Co. (7XP) stock in 2025Quarterly Profit Review & Community Driven Trade Alerts - newser.com
Organon & Co. $OGN Stake Lessened by Sound Income Strategies LLC - MarketBeat
Dakota Wealth Management Has $151,000 Stock Position in Organon & Co. $OGN - MarketBeat
Co. (7XP) stock considered safe havenPortfolio Return Report & AI Enhanced Execution Alerts - newser.com
Organon (OGN) Outperforms Broader Market: What You Need to Know - sharewise.com
Sterneck Capital Management LLC Makes New Investment in Organon & Co. $OGN - MarketBeat
Register Financial Advisors LLC Sells 30,706 Shares of Organon & Co. $OGN - MarketBeat
Organon partners across Asia Pacific to push equitable access to contraception ahead of World Contraception Day - MediaBrief
Here's Why Organon (OGN) Fell More Than Broader Market - sharewise.com
Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock - sharewise.com
Organon & Co. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Wedmont Private Capital Acquires 106,561 Shares of Organon & Co. $OGN - MarketBeat
Organon (OGN): Examining Valuation Following European Approval of Denosumab Biosimilars - simplywall.st
Organon announces departure of chief commercial officer - MSN
Gilman Hill Asset Management LLC Sells 443,231 Shares of Organon & Co. $OGN - MarketBeat
Triumph Capital Management Acquires 47,127 Shares of Organon & Co. $OGN - MarketBeat
Organon (OGN) Stock Dips While Market Gains: Key Facts - sharewise.com
Organon gets EU approval for Prolia and Xgeva biosimilars - MSN
Douglas Lane & Associates LLC Raises Holdings in Organon & Co. $OGN - MarketBeat
Organon Q2 Preview: What to expect? - MSN
Ocugen gets EU approval for Prolia and Xgeva biosimilars - MSN
Organon (OGN) Gains EU Approval for Denosumab Biosimilars - GuruFocus
Organon gets EU approval for Prolia and Xgeva biosimilars (OGN:NYSE) - Seeking Alpha
Organon, Shanghai Henlius: EC approves marketing for Bildyos, Bilprevda - TipRanks
(denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively - Business Wire
Organon Co Stock (OGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Organon Co Stock (OGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| COX CARRIE SMITH | Director |
May 14 '25 |
Buy |
8.07 |
12,469 |
100,591 |
12,469 |
| Falcione Aaron | Chief Human Resources Officer |
May 07 '25 |
Buy |
8.77 |
5,500 |
48,235 |
62,974 |
| Weaver Kirke | Gen. Counsel & Corp. Secy. |
May 06 '25 |
Buy |
9.21 |
8,045 |
74,054 |
52,489 |
| Karp Daniel | Executive VP, Corp. Dev. |
May 06 '25 |
Buy |
8.24 |
3,500 |
28,828 |
46,669 |
| WALSH MATTHEW M | Chief Financial Officer |
May 05 '25 |
Buy |
8.82 |
11,400 |
100,548 |
144,484 |
| Ali Kevin | Chief Executive Officer |
May 05 '25 |
Buy |
8.80 |
34,000 |
299,370 |
282,731 |
| Falcione Aaron | Chief Human Resources Officer |
Mar 31 '25 |
Option Exercise |
0.00 |
18,732 |
0 |
59,237 |
| Karp Daniel | Executive VP, Corp. Dev. |
Mar 31 '25 |
Option Exercise |
0.00 |
34,677 |
0 |
44,515 |
| Stahler Rachel A | Chief Information Officer |
Mar 31 '25 |
Option Exercise |
0.00 |
18,334 |
0 |
78,994 |
| WALSH MATTHEW M | Chief Financial Officer |
Mar 31 '25 |
Option Exercise |
0.00 |
34,870 |
0 |
136,903 |
1.48%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):